Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model

Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Veterinary & comparative oncology 2018-12, Vol.16 (4), p.478-488
Hauptverfasser: Rici, R. E. G., Will, S. E. A. L., Luna, A. C. L., Melo, L. F., Santos, A. C., Rodrigues, R. F., Leandro, R. M., Maria, D. A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 488
container_issue 4
container_start_page 478
container_title Veterinary & comparative oncology
container_volume 16
creator Rici, R. E. G.
Will, S. E. A. L.
Luna, A. C. L.
Melo, L. F.
Santos, A. C.
Rodrigues, R. F.
Leandro, R. M.
Maria, D. A.
description Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy.
doi_str_mv 10.1111/vco.12404
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_vco_12404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>VCO12404</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3254-1f7f3ac16dfc714af38bbd0e87f0c8fe86861c282c3b8581d06fa92d975c6a8d3</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWw4AeQt0iktZ2Xs0QRL6lSN8A2cvygRokd2aFVPoJ_xm3a7vBiPJo5c0dzAbjFaI7DW2y4nWOSoOQMTHGSZ1FKSXF-yjGagCvvvxEiJInJJZiQIqeYpOkU_Ja2rbVhvbYG9mvpWDdAqyBnRhsJre-l9cxx2zK41f362KhtCC1zzm5hYFrIZdP4h0Pdum5tv6SRveawc7aX2kBmRJh2te2asM7AfWkXN3pjw4yQzTW4UKzx8ubwz8DH89N7-RotVy9v5eMy4jFJkwirXMWM40wonuOEqZjWtUCS5gpxqiTNaIY5oYTHNQ33C5QpVhBR5CnPGBXxDNyPutxZ751UVed0uGaoMKp2llbB0mpvaWDvRrb7qVspTuTRwwAsRmCrGzn8r1R9lqtR8g8VEYPp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Rici, R. E. G. ; Will, S. E. A. L. ; Luna, A. C. L. ; Melo, L. F. ; Santos, A. C. ; Rodrigues, R. F. ; Leandro, R. M. ; Maria, D. A.</creator><creatorcontrib>Rici, R. E. G. ; Will, S. E. A. L. ; Luna, A. C. L. ; Melo, L. F. ; Santos, A. C. ; Rodrigues, R. F. ; Leandro, R. M. ; Maria, D. A.</creatorcontrib><description>Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy.</description><identifier>ISSN: 1476-5810</identifier><identifier>EISSN: 1476-5829</identifier><identifier>DOI: 10.1111/vco.12404</identifier><identifier>PMID: 29781255</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>animal models ; Animals ; antineoplastic ; Antineoplastic Agents - administration &amp; dosage ; Antineoplastic Agents - therapeutic use ; Bone Marrow Transplantation - methods ; Bone Marrow Transplantation - veterinary ; Bone Morphogenetic Protein 2 - administration &amp; dosage ; Bone Morphogenetic Protein 2 - therapeutic use ; Bone Neoplasms - therapy ; Bone Neoplasms - veterinary ; Carboplatin - administration &amp; dosage ; Carboplatin - therapeutic use ; Combined Modality Therapy - veterinary ; Disease Models, Animal ; Dog Diseases - therapy ; Dogs ; Female ; Flow Cytometry - veterinary ; Male ; Mice, Inbred BALB C ; Mice, Nude ; MSCs ; Neoplasms, Experimental - therapy ; Osteosarcoma - therapy ; Osteosarcoma - veterinary ; Real-Time Polymerase Chain Reaction ; Recombinant Proteins ; rhBMP‐2 therapy ; Stem Cell Transplantation - methods ; Stem Cell Transplantation - veterinary ; tumour</subject><ispartof>Veterinary &amp; comparative oncology, 2018-12, Vol.16 (4), p.478-488</ispartof><rights>2018 John Wiley &amp; Sons Ltd</rights><rights>2018 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3254-1f7f3ac16dfc714af38bbd0e87f0c8fe86861c282c3b8581d06fa92d975c6a8d3</citedby><cites>FETCH-LOGICAL-c3254-1f7f3ac16dfc714af38bbd0e87f0c8fe86861c282c3b8581d06fa92d975c6a8d3</cites><orcidid>0000-0001-6573-5612</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fvco.12404$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fvco.12404$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29781255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rici, R. E. G.</creatorcontrib><creatorcontrib>Will, S. E. A. L.</creatorcontrib><creatorcontrib>Luna, A. C. L.</creatorcontrib><creatorcontrib>Melo, L. F.</creatorcontrib><creatorcontrib>Santos, A. C.</creatorcontrib><creatorcontrib>Rodrigues, R. F.</creatorcontrib><creatorcontrib>Leandro, R. M.</creatorcontrib><creatorcontrib>Maria, D. A.</creatorcontrib><title>Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model</title><title>Veterinary &amp; comparative oncology</title><addtitle>Vet Comp Oncol</addtitle><description>Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy.</description><subject>animal models</subject><subject>Animals</subject><subject>antineoplastic</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bone Marrow Transplantation - methods</subject><subject>Bone Marrow Transplantation - veterinary</subject><subject>Bone Morphogenetic Protein 2 - administration &amp; dosage</subject><subject>Bone Morphogenetic Protein 2 - therapeutic use</subject><subject>Bone Neoplasms - therapy</subject><subject>Bone Neoplasms - veterinary</subject><subject>Carboplatin - administration &amp; dosage</subject><subject>Carboplatin - therapeutic use</subject><subject>Combined Modality Therapy - veterinary</subject><subject>Disease Models, Animal</subject><subject>Dog Diseases - therapy</subject><subject>Dogs</subject><subject>Female</subject><subject>Flow Cytometry - veterinary</subject><subject>Male</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>MSCs</subject><subject>Neoplasms, Experimental - therapy</subject><subject>Osteosarcoma - therapy</subject><subject>Osteosarcoma - veterinary</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Recombinant Proteins</subject><subject>rhBMP‐2 therapy</subject><subject>Stem Cell Transplantation - methods</subject><subject>Stem Cell Transplantation - veterinary</subject><subject>tumour</subject><issn>1476-5810</issn><issn>1476-5829</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWw4AeQt0iktZ2Xs0QRL6lSN8A2cvygRokd2aFVPoJ_xm3a7vBiPJo5c0dzAbjFaI7DW2y4nWOSoOQMTHGSZ1FKSXF-yjGagCvvvxEiJInJJZiQIqeYpOkU_Ja2rbVhvbYG9mvpWDdAqyBnRhsJre-l9cxx2zK41f362KhtCC1zzm5hYFrIZdP4h0Pdum5tv6SRveawc7aX2kBmRJh2te2asM7AfWkXN3pjw4yQzTW4UKzx8ubwz8DH89N7-RotVy9v5eMy4jFJkwirXMWM40wonuOEqZjWtUCS5gpxqiTNaIY5oYTHNQ33C5QpVhBR5CnPGBXxDNyPutxZ751UVed0uGaoMKp2llbB0mpvaWDvRrb7qVspTuTRwwAsRmCrGzn8r1R9lqtR8g8VEYPp</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Rici, R. E. G.</creator><creator>Will, S. E. A. L.</creator><creator>Luna, A. C. L.</creator><creator>Melo, L. F.</creator><creator>Santos, A. C.</creator><creator>Rodrigues, R. F.</creator><creator>Leandro, R. M.</creator><creator>Maria, D. A.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-6573-5612</orcidid></search><sort><creationdate>201812</creationdate><title>Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model</title><author>Rici, R. E. G. ; Will, S. E. A. L. ; Luna, A. C. L. ; Melo, L. F. ; Santos, A. C. ; Rodrigues, R. F. ; Leandro, R. M. ; Maria, D. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3254-1f7f3ac16dfc714af38bbd0e87f0c8fe86861c282c3b8581d06fa92d975c6a8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>animal models</topic><topic>Animals</topic><topic>antineoplastic</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bone Marrow Transplantation - methods</topic><topic>Bone Marrow Transplantation - veterinary</topic><topic>Bone Morphogenetic Protein 2 - administration &amp; dosage</topic><topic>Bone Morphogenetic Protein 2 - therapeutic use</topic><topic>Bone Neoplasms - therapy</topic><topic>Bone Neoplasms - veterinary</topic><topic>Carboplatin - administration &amp; dosage</topic><topic>Carboplatin - therapeutic use</topic><topic>Combined Modality Therapy - veterinary</topic><topic>Disease Models, Animal</topic><topic>Dog Diseases - therapy</topic><topic>Dogs</topic><topic>Female</topic><topic>Flow Cytometry - veterinary</topic><topic>Male</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>MSCs</topic><topic>Neoplasms, Experimental - therapy</topic><topic>Osteosarcoma - therapy</topic><topic>Osteosarcoma - veterinary</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Recombinant Proteins</topic><topic>rhBMP‐2 therapy</topic><topic>Stem Cell Transplantation - methods</topic><topic>Stem Cell Transplantation - veterinary</topic><topic>tumour</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rici, R. E. G.</creatorcontrib><creatorcontrib>Will, S. E. A. L.</creatorcontrib><creatorcontrib>Luna, A. C. L.</creatorcontrib><creatorcontrib>Melo, L. F.</creatorcontrib><creatorcontrib>Santos, A. C.</creatorcontrib><creatorcontrib>Rodrigues, R. F.</creatorcontrib><creatorcontrib>Leandro, R. M.</creatorcontrib><creatorcontrib>Maria, D. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Veterinary &amp; comparative oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rici, R. E. G.</au><au>Will, S. E. A. L.</au><au>Luna, A. C. L.</au><au>Melo, L. F.</au><au>Santos, A. C.</au><au>Rodrigues, R. F.</au><au>Leandro, R. M.</au><au>Maria, D. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model</atitle><jtitle>Veterinary &amp; comparative oncology</jtitle><addtitle>Vet Comp Oncol</addtitle><date>2018-12</date><risdate>2018</risdate><volume>16</volume><issue>4</issue><spage>478</spage><epage>488</epage><pages>478-488</pages><issn>1476-5810</issn><eissn>1476-5829</eissn><abstract>Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>29781255</pmid><doi>10.1111/vco.12404</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6573-5612</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1476-5810
ispartof Veterinary & comparative oncology, 2018-12, Vol.16 (4), p.478-488
issn 1476-5810
1476-5829
language eng
recordid cdi_crossref_primary_10_1111_vco_12404
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects animal models
Animals
antineoplastic
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Bone Marrow Transplantation - methods
Bone Marrow Transplantation - veterinary
Bone Morphogenetic Protein 2 - administration & dosage
Bone Morphogenetic Protein 2 - therapeutic use
Bone Neoplasms - therapy
Bone Neoplasms - veterinary
Carboplatin - administration & dosage
Carboplatin - therapeutic use
Combined Modality Therapy - veterinary
Disease Models, Animal
Dog Diseases - therapy
Dogs
Female
Flow Cytometry - veterinary
Male
Mice, Inbred BALB C
Mice, Nude
MSCs
Neoplasms, Experimental - therapy
Osteosarcoma - therapy
Osteosarcoma - veterinary
Real-Time Polymerase Chain Reaction
Recombinant Proteins
rhBMP‐2 therapy
Stem Cell Transplantation - methods
Stem Cell Transplantation - veterinary
tumour
title Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T02%3A23%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20therapy%20of%20canine%20osteosarcoma%20with%20canine%20bone%20marrow%20stem%20cells,%20bone%20morphogenetic%20protein%20and%20carboplatin%20in%20an%20in%20vivo%20model&rft.jtitle=Veterinary%20&%20comparative%20oncology&rft.au=Rici,%20R.%20E.%20G.&rft.date=2018-12&rft.volume=16&rft.issue=4&rft.spage=478&rft.epage=488&rft.pages=478-488&rft.issn=1476-5810&rft.eissn=1476-5829&rft_id=info:doi/10.1111/vco.12404&rft_dat=%3Cwiley_cross%3EVCO12404%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/29781255&rfr_iscdi=true